Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Cash from Financing Activities for 6 consecutive years, with -$134130.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 173.72% to -$134130.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $99.6 million, a 2624.47% increase, with the full-year FY2024 number at $103.5 million, up 1131.14% from a year prior.
  • Cash from Financing Activities was -$134130.0 for Q3 2025 at Inhibikase Therapeutics, down from $31771.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $99.7 million in Q4 2024 to a low of -$409662.0 in Q1 2021.
  • A 5-year average of $10.9 million and a median of $30831.5 in 2021 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 1692893.51% in 2021; the steepest drop was 263.79% in 2021.
  • Inhibikase Therapeutics' Cash from Financing Activities stood at $29892.0 in 2021, then tumbled by 785.03% to -$204769.0 in 2022, then surged by 32.56% to -$138104.0 in 2023, then soared by 72280.72% to $99.7 million in 2024, then plummeted by 100.13% to -$134130.0 in 2025.
  • Per Business Quant, the three most recent readings for IKT's Cash from Financing Activities are -$134130.0 (Q3 2025), $31771.0 (Q2 2025), and $99.7 million (Q4 2024).